151. Allele-specific editing ameliorates dominant retinitis pigmentosa in a transgenic mouse model.
- Author
-
Patrizi C, Llado M, Benati D, Iodice C, Marrocco E, Guarascio R, Surace EM, Cheetham ME, Auricchio A, and Recchia A
- Subjects
- Alleles, Animals, CRISPR-Cas Systems, Cell Line, Dependovirus genetics, Disease Models, Animal, Electroretinography, Genetic Therapy, Humans, INDEL Mutation, Mice, Mice, Transgenic, Mutation, Missense, Photoreceptor Cells, Vertebrate metabolism, Retina metabolism, Retina physiopathology, Rhodopsin metabolism, Gene Editing, Retinitis Pigmentosa genetics, Retinitis Pigmentosa therapy, Rhodopsin genetics
- Abstract
Retinitis pigmentosa (RP) is a group of progressive retinal degenerations of mostly monogenic inheritance, which cause blindness in about 1:3,500 individuals worldwide. Heterozygous variants in the rhodopsin (RHO) gene are the most common cause of autosomal dominant RP (adRP). Among these, missense variants at C-terminal proline 347, such as p.Pro347Ser, cause severe adRP recurrently in European affected individuals. Here, for the first time, we use CRISPR/Cas9 to selectively target the p.Pro347Ser variant while preserving the wild-type RHO allele in vitro and in a mouse model of adRP. Detailed in vitro, genomic, and biochemical characterization of the rhodopsin C-terminal editing demonstrates a safe downregulation of p.Pro347Ser expression leading to partial recovery of photoreceptor function in a transgenic mouse model treated with adeno-associated viral vectors. This study supports the safety and efficacy of CRISPR/Cas9-mediated allele-specific editing and paves the way for a permanent and precise correction of heterozygous variants in dominantly inherited retinal diseases., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF